Director Global Strategic Planning - Digital Transformation, Sandoz International

Location: Holzkirchen, Germany
Job Type: Full-Time
Employer: Sandoz (Novartis Group)
Sandoz is currently recruiting for a Director Global Strategic Planning - Digital Transformation to join our Global Strategic Team to lead large-scale, global strategic initiatives to drive significant business improvement in digital area.

The purpose of the Director Global Strategic Planning role is to Manage multiple, cross-functional project teams ensuring rapid results generation of assigned initiatives.

Key Responsibilities

  • Set the digital aspiration for Sandoz and translate that into a tangible roadmap for the next 3-5 years and beyond
  • Closely collaborate with all Novartis divisions to identify synergies and opportunities along digital agenda and solutions
  • Drive the implementation across functions and geographies in Sandoz and track the success
  • Work with key stakeholders in top management to enable their “digital readiness” and informed decision making
  • Build and coordinate a small capable team to develop solutions on how we innovate, sell and operate
  • Act as the crystallization point for all digital topics of strategic value between Sandoz and external world, i.e.,
  • Respond to or identify business challenges within Sandoz which could be resolved by digital solutions and coordinate the solution
  • Identify new business models in the market (products and services) that may be a model for Sandoz and push their adoption in the division
  • Actively identify and start collaborations with external parties (e.g., startups) which can also be exploratory in nature
  • Help initiatives and colleagues (individually or in groups) to become more digital, more agile and more customer-centric

Minimum requirements

  • Significant experience at top tier consultancy (with relevant CXO interaction)
  • Proven experience as project manager is a must-have, ideally
  • First-hand experience in developing and delivering digital strategies/transformations along e.g,. multi-channel, web-enabled design, big data analytics, cloud computing, e-commerce etc.
  • Highly desired: Demonstrable track-record in building digital businesses, particularly as a founder
  • Savviness in innovative digital trends, e.g. IoT, Blockchain, Artificial Intelligence, Neural Networks etc
  • Top academic achievements
  • Fluency in English & at least 1 additional European language
  • Tested capability to successfully lead teams and projects, often with tight time constraints
  • Entrepreneurial spirit with Can-do, pro-active attitude
  • Excellent communication and presentation skills

Apply for this job

About Sandoz
Sandoz is a global leader in generic pharmaceuticals and biosimilars. As a division of the Novartis Group, our purpose is to discover new ways to improve and extend people’s lives. We contribute to society’s ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. Our portfolio of approximately 1000 molecules, covering all major therapeutic areas, accounted for 2016 sales of USD 10.1 billion. In 2016, our products reached well over 500 million patients and we aspire to reach one billion. Sandoz is headquartered in Holzkirchen, in Germany’s Greater Munich area.

Sandoz Biopharmaceuticals, a global business unit of Sandoz, comprises biosimilars, contract manufacturing and Glatopa 20mg (glatiramer acetate). It is a USD one billion business (2016 annual sales). As the pioneer and global leader in biosimilars, with sales in 86 countries and five marketed biosimilars in Europe, Sandoz is committed to increasing patient access to high-quality, life-enhancing biosimilars. Its biosimilar products (Omnitrope, Binocrit, Zarzio/Zarzio, Rixathon and Erelzi) have generated more than 340 million patient days of experience. Sandoz has a leading biosimilar pipeline and plans to launch a total of five biosimilars of major oncology and immunology biologics across major markets between 2017 and 2020. A division of the Novartis Group, Sandoz is well-positioned to continue leading the biosimilars industry based on its experience and capabilities in development, manufacturing, and commercialization.

Post your job offer now to start hiring the best digital health talent! For further information, please contact us.

Most Popular Now

Artificial Intelligence: Unexpected Resu…

Artificial intelligence (AI) is on the rise. Until now, AI applications generally have "black box" character: How AI arrives at its results remains hidden. Prof. Dr. Jürgen Bajorath, a cheminformatics...

Printed Robots with Bones, Ligaments, an…

3D printing is advancing rapidly, and the range of materials that can be used has expanded considerably. While the technology was previously limited to fast-curing plastics, it has now been...

AI identifies Non-Smokers at High Risk f…

Using a routine chest X-ray image, an artificial intelligence (AI) tool can identify non-smokers who are at high risk for lung cancer, according to a study being presented next week...

Orchestrating the New World of AI in Hea…

Orion Health's UK and Ireland Customer Conference 2023 focused on the future potential and immediate, practical application of AI to healthcare - and gave delegates a first look at the...

Study Reveals Bias in AI Tools when Diag…

Machine learning algorithms designed to diagnose a common infection that affects women showed a diagnostic bias among ethnic groups, University of Florida researchers found. While artificial intelligence (AI) tools offer...

Researchers Take New AI Approach to Anal…

Researchers at Karolinska Institutet and SciLifeLab in Sweden have combined artificial intelligence (AI) techniques used in satellite imaging and community ecology to interpret large amounts of data from tumour tissue...

Medical AI Tool from UF, NVIDIA gets Hum…

A new artificial intelligence (AI) computer program created by researchers at the University of Florida and NVIDIA can generate doctors' notes so well that two physicians couldn't tell the difference...

Commission Opens Calls to Invest €42 Mil…

Today, the European Commission opened a new set of calls for proposals under the 2023-2024 Work Programmes of the Digital Europe Programme with a focus on advanced digital skills. The calls...

Bayer Championing Advancements in Radiol…

Bayer continues to advance its comprehensive Radiology portfolio with progress in the development pipeline of its investigational contrast agent as well as new innovations in the area of Artificial Intelligence...

MEDICA and COMPAMED: Medical Technology …

13 - 16 November 2023, Düsseldorf, Germany. After four days of business, MEDICA and COMPAMED in Düsseldorf delivered impressive confirmation that they are excellent platforms for the worldwide medical technology business...

AI Predicts Developmental Paths in Prema…

Researchers at UMC Utrecht have developed an AI model to predict long-term outcome in extremely premature babies early in life. The model can identify which infants might face intellectual disability...

AI Paves Way for New Medicines

A team of researchers from LMU, ETH Zurich, and Roche Pharma Research and Early Development (pRED) Basel has used artificial intelligence (AI) to develop an innovative method that predicts the...